Hazel M. Weir

Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists

Weiyi Toy, Hazel M. Weir, Pedram Razavi et al. · Cancer Discovery · 2016 · 370 citations · Full text

Medicine, Endocrinology, Oncology +17

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i> -Mutant Breast Tumors in Preclinical Models

Hazel M. Weir, Robert H. Bradbury, Mandy Lawson et al. · Cancer Research · 2016 · 174 citations

Medicine, Oncology, Pharmacology +16

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models

Amir Bahreini, Zheqi Li, Peilu Wang et al. · Breast Cancer Research · 2017 · 162 citations · Full text

Life Sciences, Genetics, Oncology +17

Optimization of a Novel Binding Motif to (<i>E</i>)-3-(3,5-Difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-<i>b</i>]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

Chris De Savi, Robert H. Bradbury, Alfred A. Rabow et al. · Journal of Medicinal Chemistry · 2015 · 160 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer

Erika Hamilton, Manish R. Patel, Anne Armstrong et al. · Clinical Cancer Research · 2018 · 89 citations · Full text

Medicine, Oncology, Pharmacology +11